scholarly journals Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration

mAbs ◽  
2012 ◽  
Vol 4 (2) ◽  
pp. 243-255 ◽  
Author(s):  
Yanan Zheng ◽  
Devin B. Tesar ◽  
Lisa Benincosa ◽  
Herbert Birnböck ◽  
C. Andrew Boswell ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Subcutaneous Administration ◽  
Antibody Pharmacokinetics

scholarly journals Towardin vitro-to-in vivotranslation of monoclonal antibody pharmacokinetics: Application of a neonatal Fc receptor-mediated transcytosis assay to understand the interplaying clearance mechanisms

mAbs ◽  
2017 ◽  
Vol 9 (5) ◽  
pp. 781-791 ◽  
Author(s):  
Claudia A. Castro Jaramillo ◽  
Sara Belli ◽  
Anne-Christine Cascais ◽  
Sherri Dudal ◽  
Martin R. Edelmann ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Fc Receptor ◽  
Neonatal Fc Receptor ◽  
Antibody Pharmacokinetics

scholarly journals IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

Blood ◽  
1997 ◽  
Vol 90 (6) ◽  
pp. 2188-2195 ◽  
Author(s):  
David G. Maloney ◽  
Antonio J. Grillo-López ◽  
Christine A. White ◽  
David Bodkin ◽  
Russell J. Schilder ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
B Cell ◽  
Specific Antigen ◽  
Antibody Therapy ◽  
High Serum ◽  
Low Grade ◽  
Antibody Pharmacokinetics ◽  
Anti Cd20 ◽  
Hodgkin's Lymphomas

Abstract IDEC-C2B8 is a chimeric monoclonal antibody (MoAb) directed against the B-cell–specific antigen CD20 expressed on non-Hodgkin's lymphomas (NHL). The MoAb mediates complement and antibody-dependent cell-mediated cytotoxicity and has direct antiproliferative effects against malignant B-cell lines in vitro. Phase I trials of single doses up to 500 mg/m2 and 4 weekly doses of 375 mg/m2 showed clinical responses with no dose-limiting toxicity. We conducted a phase II, multicenter study evaluating four weekly infusions of 375 mg/m2 IDEC-C2B8 in patients with relapsed low-grade or follicular NHL (Working Formulation groups A-D). Patients were monitored for adverse events, antibody pharmacokinetics, and clinical response. Thirty-seven patients with a median age of 58 years (range, 29 to 81 years) were treated. All patients had relapsed after chemotherapy (median of 2 prior regimens) and 54% had failed aggressive chemotherapy. Infusional side effects (grade 1-2) consisting of mild fever, chills, respiratory symptoms, and occasionally hypotension were observed mostly with the initial antibody infusion and were rare with subsequent doses. Peripheral blood B-cell depletion occurred rapidly, with recovery beginning 6 months posttreatment. There were no significant changes in mean IgG levels and infections were not increased over what would be expected in this population. Clinical remissions were observed in 17 patients (3 complete remissions and 14 partial remissions), yielding an intent to treat response rate of 46%. The onset of these tumor responses was as soon as 1 month posttreatment and reached a maximum by 4 months posttreatment. In the 17 responders, the median time to progression was 10.2 months (5 patients exceeding 20 months). Likelihood of tumor response was associated with a follicular histology, with the ability to sustain a high serum level of antibody after the first infusion, and with a longer duration of remission to prior chemotherapy. One patient developed a detectable but not quantifiable immune response to the antibody that had no clinical significance. IDEC-C2B8 in a dose of 375 mg/m2 weekly for 4 weeks has antitumor activity in patients with relapsed low-grade or follicular NHL. Results with this brief, outpatient treatment compare favorably with results with standard chemotherapy, and IDEC-C2B8 has a better safety profile. Further studies evaluating IDEC-C2B8 in other types of lymphoma either alone or combined with chemotherapy are warranted.

Sign in / Sign up

Export Citation Format

Share Document